Bracket, a clinical trial technology and specialty services provider, announced the release of CUBE, a transformative interactive response technology (IRT) solution for the life sciences industry. Designed through an iterative user acceptance build experience, CUBE will be immediately available to qualifying biotechnology and pharmaceutical trial sponsors through Bracket.
The solution will enable biotech and pharma sponsors to utilize an innovative new solution to deploy studies in one to two weeks. It leverages an iterative user acceptance build experience to provide a rapid and advanced deployment methodology without the time and cost constraints of traditional IRT solutions. Key highlights of CUBE for biotech and pharma sponsors of any size include:
Accelerate times for sponsors and improves efficiency for CROs
Leverages Bracket's full RTSM platform, but streamlines deployment through automation
Rapid project lifecycle lets sponsors experience the system prior to requirements approval
Reduce lengthy turnaround times for enhancements and in-study changes
"We're so pleased to introduce CUBE to the life sciences marketplace and are confident that its easy-to-implement nature will improve the process of managing clinical supplies," said Jeff Kinell, CEO at Bracket. "By deemphasizing requirement documents and prioritizing unique configuration needs, CUBE will undoubtedly evolve the paradigm of how sponsors collaborate to deploy IRT."
The platform's iterative UAT process allows study teams to visualize the RTSM system during the kick off meeting. This accelerates timelines for sponsors and improves efficiency for CROs. CUBE also leverages Bracket's full RTSM platform, but streamlines the deployment of configuration profiles through automation. It's intended to support most trial design constructs.
